Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M

57 minutes ago 1

Maham Fatima

Thu, May 21, 2026 astatine 8:30 AM CDT 2 min read

Viridian Therapeutics Inc. (NASDAQ:VRDN) is 1 of the best debased priced stocks to bargain for the adjacent 3 years. On May 6, Viridian Therapeutics announced the pricing of upsized concurrent nationalist offerings totaling $350 cardinal successful aggregate gross proceeds. The financing consists of $225 cardinal successful 1.75% convertible elder notes owed 2032 and an equity offering of 7,352,942 shares of communal banal priced astatine $17.00 per share. Net proceeds are estimated astatine $334.7 million, with underwriters granted 30-day options to acquisition up to an further $25 cardinal successful notes and 1,102,941 shares of communal stock.

The convertible notes volition beryllium unsecured, elder obligations maturing connected May 15, 2032, with involvement payable semi-annually. The archetypal conversion complaint is acceptable astatine 40.5680 shares per $1,000 main amount, representing an archetypal conversion terms of astir $24.65 per stock and a 45.0% premium implicit the nationalist equity offering price. Viridian retains the enactment to redeem the notes connected oregon aft May 20, 2030, provided its banal terms exceeds 130% of the conversion terms for a specified trading duration.

Viridian Therapeutics (VRDN) Prices Upsized Concurrent Public Offerings Totaling $350M

Viridian Therapeutics Inc. (NASDAQ:VRDN) plans to usage the nett proceeds to afloat repay its outstanding indebtedness with Hercules Capital Inc. The remaining superior volition money marketplace enlargement studies for its thyroid oculus illness franchise, beforehand early-stage pipeline research, and enactment wide moving superior needs.

Viridian Therapeutics Inc. (NASDAQ:VRDN) discovers and sells treatments for uncommon and superior illnesses. It produces 3 main therapeutics: Veligrotrug, Elegrobart, and anti-thyroid-stimulating hormone receptor/TSHR. Its portfolio of engineered inhibitors of the neonatal Fc receptor (FcRn) includes VRDN-008 and VRDN-006.

While we admit the imaginable of VRDN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.

Read Entire Article